Last reviewed · How we verify

NCT05927272: STRAVI

Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions

Recruiting now NA Last updated 19 April 2024
What this trial tests

NA trial testing SKIN SAMPLES in Vitiligo in 10 participants. Currently enrolling.

Timeline
10 April 2024
Primary endpoint
9 October 2025
9 October 2025

Quick facts

Lead sponsorUniversity Hospital, Bordeaux
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment10
Start date10 April 2024
Primary completion9 October 2025
Estimated completion9 October 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bordeaux

Who can join

Adults 18 to 65, any sex, with Vitiligo. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to perform an in-depth analysis of the molecular pathways involved in lesions responding to current treatment and lesions not responding to current treatment

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Vitiligo

Currently open trials in the same condition.

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05927272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing